The expansion into alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) represents strategic portfolio diversification. These conditions affect millions globally with limited treatment options, potentially creating multiple revenue streams from a single asset. The appointment of Jerry Durso as Chairman signals preparation for commercialization, leveraging his extensive commercial expertise as Altimmune transitions from clinical development toward potential market entry. This leadership change, aligned with advancing pemvidutide to Phase 3, indicates confidence in their clinical program and focus on building commercial infrastructure ahead of potential approval.